← Back to Search

Hormone Therapy

Glucagon for Type 2 Diabetes

Phase 1
Waitlist Available
Led By Kitt F Petersen, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Taking no medications except birth control
T2D fasting plasma glucose 126 - 200 mg/dL, HbA1c >9%, taking metformin, sulfonylureas, DPP4 inhibitors or SGLT2 inhibitors or diet controlled
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 hours
Awards & highlights

Study Summary

This trial will study the effects of glucagon on mitochondrial oxidation and pyruvate carboxylase flux in humans to see if it's a possible treatment for type 2 diabetes.

Who is the study for?
This trial is for healthy, non-smoking individuals or those with type 2 diabetes (T2D) who have fasting plasma glucose levels between 126 - 200 mg/dL and HbA1c over 9%. Participants can be on metformin, sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors or just diet-controlled. They must not be taking any medications except birth control and should not have any diseases other than NAFLD/NASH or T2D.Check my eligibility
What is being tested?
The study is testing the effects of glucagon on hepatic mitochondrial oxidation in humans using PINTA analysis. It aims to understand how glucagon influences liver glucose production and could impact treatments for fatty liver disease and T2D by exploring dual GLP-1/glucagon receptor antagonism.See study design
What are the potential side effects?
While specific side effects are not listed here, interventions like glucagon may cause changes in blood sugar levels which need to be monitored closely during the trial due to its role in regulating glucose metabolism.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am only taking birth control medication.
Select...
My fasting blood sugar is between 126-200 mg/dL, my HbA1c is over 9%, and I'm managing my type 2 diabetes with medication or diet.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rates of Hepatic Glucose production
Rates of Hepatic Ketogenesis
Echinococcosis, Hepatic

Trial Design

1Treatment groups
Experimental Treatment
Group I: GlucagonExperimental Treatment1 Intervention
Participants will receive glucagon or saline during the PINTA study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Glucagon
2016
Completed Phase 4
~590

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,886 Previous Clinical Trials
5,054,528 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,357 Previous Clinical Trials
4,315,161 Total Patients Enrolled
Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,737,643 Total Patients Enrolled

Media Library

Glucagon (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03965130 — Phase 1
Healthy Subjects Research Study Groups: Glucagon
Healthy Subjects Clinical Trial 2023: Glucagon Highlights & Side Effects. Trial Name: NCT03965130 — Phase 1
Glucagon (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03965130 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial admit individuals under the age of 65?

"This experiment is looking for volunteers who are below the age of 75 and have reached their majority."

Answered by AI

How many individuals are actively engaged in this clinical research?

"This clinical trial is no longer accepting new participants. The post was initially made on May 22nd 2019, and the last update occurred on January 17th 2022. For those looking for alternative studies, 839 trials are presently enrolling patients with Pinta and there are 8 Glucagon-related medical experiments actively recruiting volunteers."

Answered by AI

What is the criteria for eligibility in this experiment?

"This medical investigation is seeking 18 patients with pinta, aged 21 to 75 years old. In addition, those taking part must be non-smokers and not use any medication except contraception."

Answered by AI

Are individuals still being accepted to join this research?

"The clinicaltrials.gov website states that this medical trial is not recruiting at present; it was first posted on May 22nd 2019 and the last update came through on January 17th 2022. Despite this, 847 other trials are still taking patients immediately."

Answered by AI

In what type of situations is Glucagon typically prescribed?

"Glucagon has been clinically proven to be an effective remedy for type 2 diabetes mellitus, diabetes, and hypoglycemia."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
2019. "The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03965130.
~14 spots leftby Dec 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top